Remel, Inc Xpect Giardia/Cryptosporidium Kit, Ref 24050520, 20 tests per kit, For In Vitro Diagnostic Use. A rapid test for the direct qualitative detection of Giardia and Cryptosporidium antigens in fecal specimens. Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Xpect Giardia/Cryptosporidium Kit, Ref 24050520, 20 tests per kit, For In Vitro Diagnostic Use. A rapid test for the direct qualitative detection of Giardia and Cryptosporidium antigens in fecal specimens.
Brand
Remel, Inc
Lot Codes / Batch Numbers
Lot numbers 597374, Exp. 2008.10.08, 607636, Exp. 2008.11.06, 615970, Exp. 2008.12.02, 615971, Exp. 2008.12.02, 621187, Exp. 2008.12.02, 622617, Exp. 2009.04.02, 624618, Exp. 2009.01.02, 635553, Exp. 2009.04.17, 635554, Exp. 2009.04.24, 640609, Exp. 2009.05.01, 654829, Exp. 2009.05.30, and 658878, Exp. 2009.05.30
Products Sold
Lot numbers 597374, Exp. 2008.10.08; 607636, Exp. 2008.11.06; 615970, Exp. 2008.12.02; 615971, Exp. 2008.12.02; 621187, Exp. 2008.12.02; 622617, Exp. 2009.04.02; 624618, Exp. 2009.01.02; 635553, Exp. 2009.04.17; 635554, Exp. 2009.04.24; 640609, Exp. 2009.05.01; 654829, Exp. 2009.05.30; and 658878, Exp. 2009.05.30
Remel, Inc is recalling Xpect Giardia/Cryptosporidium Kit, Ref 24050520, 20 tests per kit, For In Vitro Diagnostic Use. A r due to Faint grey test lines for Cryptosporidium may be visible which may be interpreted as false positive. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Faint grey test lines for Cryptosporidium may be visible which may be interpreted as false positive
Recommended Action
Per FDA guidance
The recalling firm issued letters dated 6/19/08 flagged "IMPORTANT PRODUCT INFORMATION" which advised their customers of the issue with the faint grey test lines but did not request any action be taken, such as return or destruction of the affected lot numbers. The recalling firm issued a second letter flagged "IMPORTANT MEDICAL DEVICE CUSTOMER ADVISORY NOTICE" dated 8/11/08 and was issued via regular mail on 8/14/08. This letter asked users to review their inventory for the product lots indicated in the letter, discard all remaining units of this product lot, complete and return the Product Inventory Checklist regardless if they have affected product. A "PRODUCT INVENTORY CHECKLIST" was enclosed to report whether the firm had product to discard and the amount to be replaced.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026